Results 161 to 170 of about 168,529 (313)

Cost-Effectiveness of an Insertable Cardiac Arrhythmia Monitor after Non-ST-Elevation Myocardial Infarction in the UK. [PDF]

Pharmacoecon Open
Dymond A, Barker E, Tsitiridis N, Schmetz A, Hilpert ST, Jøns C, Behrens S, Søgaard P, Green W.   +8 more
europepmc   +1 more source

Actions of a Novel Na+ and Ca++ dual channel blocker, SD-3212, on Several Animal Models of Cardiac Arrhythmias.

, 1991
F. Yamazaki, Nobuaki Miyawaki, Shiro Mita   +2 more
openalex   +1 more source

Diagnostic Value of Cardiac Magnetic Resonance in Patients with Frequent Ventricular Arrhythmia and Normal Doppler Echocardiography [PDF]

, 2013
Sebastián Maldonado, Luciano De Stefano, Diego Pérez de Arenaza, Gustavo Maid, Mariano Falconi, Marcelo Pietrani, Laura Dragonetti, Raúl Pérez Etchepare, Ricardo García Mónaco, César Belziti   +9 more
openalex   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

Dysregulation of N-terminal acetylation causes cardiac arrhythmia and cardiomyopathy. [PDF]

Nat Commun
Yoshinaga D, Craven I, Feng R, Prondzynski M, Shani K, Tharani Y, Mayourian J, Joseph M, Walker D, Bortolin RH, Carreon CK, Boss B, Upton S, Parker KK, Pu WT, Bezzerides VJ.   +15 more
europepmc   +1 more source

Gut microbiota and cardiac arrhythmia. [PDF]

Front Cell Infect Microbiol, 2023
Fan H, Liu X, Ren Z, Fei X, Luo J, Yang X, Xue Y, Zhang F, Liang B.   +8 more
europepmc   +1 more source

Automatic external defibrillator: The pros and cons of using this technology for cardiac resuscitation after arrhythmias

M. Lima, Fabíola Sousa Santos, Janaína Dourado Ramos Rôde, Laís Pinho Cruz   +3 more
openalex   +2 more sources

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Cardiac Arrhythmia: Molecular Mechanisms and Therapeutic Strategies. [PDF]

Int J Mol Sci
Okamoto Y, Tsumoto K.
europepmc   +1 more source

New synthetic cannabinoids and the potential for cardiac arrhythmia risk. [PDF]

J Mol Cell Cardiol Plus, 2023
Hancox JC, Copeland CS, Harmer SC, Henderson G.   +3 more
europepmc   +1 more source